Protagonist Therapeutics, Inc. PTGX
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) is a dermatology drug developer. Its lead program, PN-881, is in Phase 2 for Plaque psoriasis. Its next catalyst on record is PN-881: Initiation of Phase 2b dose range-finding study in plaque psoriasis (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PN-881 — Initiation of Phase 2b dose range-finding study in plaque psoriasis (Q1 2027). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ICOTYDE (icotrokinra) | Moderate-to-severe plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease | small molecule | Approved |
| MIMRYLO (rusfertide) | Erythrocytosis in polycythemia vera | protein/peptide | Approved |
| PN-881 | Immune-mediated skin diseases (plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, spondyloarthritis) | small molecule | Phase 2 |
| PN-477o (oral formulation) | Obesity | protein/peptide | Phase 1 |
| PN-458 | Obesity | protein/peptide | Pre-clinical |
| PN-8047 | Polycythemia vera | small molecule | Pre-clinical |
| Oral IL-4R alpha antagonist | Atopic dermatitis, moderate-to-severe asthma | small molecule | Pre-clinical |
| AmylinR-based mono- and poly-agonists | Obesity | protein/peptide | Pre-clinical |
Recent results and decisions
- Nov 5, 2026positive Phase 1 study of PN-881, an oral IL-17 antagonist, completed with favorable tolerability and achievement of target concentrations; Phase 2b study in psoriasis planned for early Q1 2027.
PN-881 achieved 24-hour trough concentrations several-fold above prospectively targeted IC90 values for IL-17AA, IL-17FF and IL-17AA+FF with once-daily oral dosing and was generally well tolerated, with no serious adverse events.
Filing - Nov 5, 2026positive Phase 1 SAD study of PN-477sc (triple GLP-1/GIP/GCG agonist) showed positive dose-related activity; company prioritizes oral formulation with Phase 1 anticipated in H1 2027.
In the subcutaneously administered PN-477sc Phase 1 SAD study we observed positive dose-related pharmacokinetic, pharmacodynamic and clinical activity.
Filing - Sep 30, 2026approval MIMRYLO was approved in the United Arab Emirates.
On September 30, 2026, MIMRYLO was also approved in the United Arab Emirates.
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.